VL
Insider
Vincent S LoPriore
Executive ChairmanVincent S LoPriore (Executive Chairman) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales, 2 filed past the two-business-day deadline), most often in Hepion Pharmaceuticals, Inc. (HEPA). Across 2 priced purchase filings, the average 21-session return was +64.1% from execution and +27.9% from disclosure (delay-adjusted; derived). The largest single filing was $500K of HEPA (10,000,000 sh across 2 lots, as filed), executed Aug 3.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+64.1%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+27.9%
same 2 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells · 2 late
Median delay
8d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$700K
shares × price, as filed
Last traded
Aug 3
Filed Aug 12
Median ADV $1K across their filed names
Open performance→Volume by month
Buys $700K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
HEPARecent filings
HEPAPURCHASE
Hepion Pharmaceuticals, Inc.
View filing →
$500K10,000,000 sh across 2 lots
Exec Aug 3
Filed Aug 12 · 9:34 PM ET † HEPAPURCHASE Hepion Pharmaceuticals, Inc. View filing → $200K
5,000,000 sh × $0.04
Exec Apr 21
Filed Apr 27 · 6:24 AM ET †